News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lonza Inc. Denies $210 Million South African API Plant Deal is Done
February 15, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Lonza has denied reports it has signed a deal with the South African government to build a $210m (€159m) API plant, saying it is merely “in discussions” over plans.
Twitter
LinkedIn
Facebook
Email
Print
Real estate
Asia
Africa
MORE ON THIS TOPIC
Editorial
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
October 8, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
October 8, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart
October 8, 2026
·
2 min read
·
Gabrielle Masson
Funding
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
October 8, 2026
·
1 min read
·
Tristan Manalac
